Aquestive Therapeutics appoints Cassie Jung as COO, Stephen Wargacki as CSO

Aquestive Therapeutics has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm Sublingual Film, the Company’s epinephrine prodrug product candidate that has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the U.S. Food and Drug Administration. Sherry Korczynski joined the Aquestive leadership team as Senior Vice President, Sales and Marketing. Cassie Jung was promoted to Chief Operating Officer, and Stephen Wargacki, Ph.D., was named Chief Science Officer. Ms. Korczynski previously served as Vice President, EpiPen Marketing and Public Relations at Mylan. Stephen Wargacki joined Aquestive in 2015 and has held positions of increasing responsibility since joining the Company. Most recently, Dr. Wargacki was Aquestive’s Senior Vice President of Research and Development. Ms. Jung joined Aquestive in 2004 and has held leadership positions across various areas of the business, including Quality Assurance, Alliance Management, Clinical Operations, and Portfolio Management.